Testosterone oral - TesoRx

Drug Profile

Testosterone oral - TesoRx

Alternative Names: CDGP therapy - TesoRx; TSX-002

Latest Information Update: 06 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Western University of Health Sciences
  • Developer TesoRx
  • Class Anabolic steroids; Androstenols; Erectile dysfunction therapies; Eye disorder therapies; Hormonal replacements; Small molecules; Testosterone congeners
  • Mechanism of Action Testosterone congener stimulants; Testosterone replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hypogonadism
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Hypogonadism

Most Recent Events

  • 01 Dec 2017 Testerone oral is licensed to ASKA Pharmaceuticals in Japan and South-East Asia
  • 01 Dec 2017 A phase II study in constitutional delay in growth and puberty is planned for adolescent males in Japan in 2018
  • 19 Jan 2017 Preclinical trials in Hypogonadism (In adolescents) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top